Topic Hub
14 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Explore
Showing 14 of 14 clinical reviews.
A complete caregiver guide to administering Ozempic (semaglutide) injections in adolescents aged 12 to 17, covering dose escalation, injection technique, storage, missed doses, and safety monitoring.
Read clinical reviewA clinician-reviewed guide to transitioning adolescents on Ozempic (semaglutide) from pediatric to adult diabetes or obesity care, covering timing, dosing continuity, insurance, and monitoring protocols.
Read clinical reviewA clinician-reviewed guide covering how Ozempic (semaglutide 0.5 to 2.0 mg) affects adolescents aged 12 to 17 at school, in sports, and during daily activities, including dosing, side-effect management, and practical accommodations.
Read clinical reviewStep-by-step caregiver guidance for administering Ozempic (semaglutide) to adults 65 and older, including injection technique, hypoglycemia risk, dose titration, and storage tips backed by FDA labeling and geriatric clinical evidence.
Read clinical reviewA clinician-reviewed guide to semaglutide (Ozempic) use in geriatric patients aged 65+, covering dose adjustments, safety monitoring, transitional care handoffs, and evidence from SUSTAIN and SELECT trials.
Read clinical reviewA clinician-reviewed guide to semaglutide (Ozempic 0.5 to 2.0 mg) use in adults 65 and older, covering safe physical activity, cognitive engagement, fall risk, muscle preservation, and practical dose management.
Read clinical reviewA clinician-reviewed deep dive into how semaglutide (Ozempic) affects growth, puberty, bone density, neurodevelopment, and long-term health in adolescents ages 12 to 17, with trial data, dosing guidance, and monitoring protocols.
Read clinical reviewA physician-reviewed guide to off-label semaglutide (Ozempic) use in adolescents ages 12 to 17, covering evidence, approved alternatives, dosing considerations, risks, and clinical decision-making.
Read clinical reviewA detailed clinical guide to semaglutide 0.5 to 2.0 mg (Ozempic) use in geriatric patients aged 65+, covering off-label indications, age-specific risks, dose titration, and evidence from major trials.
Read clinical reviewA clinician-reviewed guide to semaglutide (Ozempic 0.5 to 2.0 mg) use in adults aged 65 and older, covering efficacy, safety, muscle and bone considerations, cognitive effects, and prescribing guidance from major trials and guidelines.
Read clinical reviewA clinician-reviewed guide to semaglutide (Ozempic) use in children younger than 12, covering developmental safety signals, regulatory status, trial data, and evidence-based alternatives.
Read clinical reviewA clinician-reviewed guide covering how semaglutide (Ozempic) use in children under 12 affects school attendance, physical activity, nutrition, and daily routines, with evidence-based safety guidance.
Read clinical reviewOzempic (semaglutide) is not FDA-approved for children under 12. This evidence-based guide explains the clinical field, transition planning considerations, and what to expect when a pediatric patient moves into adult GLP-1 care.
Read clinical reviewOzempic (semaglutide 0.5 to 2.0 mg) is not FDA-approved for children under 12. This clinical review covers the current evidence, guideline positions, risks, and the rare circumstances where a pediatric endocrinologist might consider off-label use.
Read clinical review